> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Aurobindo Inspection Results in 9-item Form 483
- URL: https://www.fdaweb.com/aurobindo-inspection-results-in-9-item-form-483/
- Published: 2019-06-10T12:00:00.000Z
- Updated: 2026-09-15T01:31:44.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5144295

An FDA inspection last month at Aurobindo Pharma’s Telangana, India manufacturing facility has led to a nine-observation [Form 483](https://www.fda.gov/media/127827/download?ref=fdaweb.com). The inspection cited the firm’s quality control unit because its procedures and responsibilities are not in writing and fully followed. FDA also cited the firm for not retaining a sample representative of each lot in each shipment of each active ingredient. Additionally, FDA said written procedure were not followed for equipment cleaning and maintenance.